The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
REGULATORY
Intussusception Cases within 21 Days after Rotavirus Vaccination Should Be Reported: MHLW Panels
Now that the inclusion of rotavirus vaccines in the public vaccination programs was recommended, health ministry panels agreed on September 20 that cases of intussusception confirmed within 21 days after administration of rotavirus vaccines should be subject to reporting as…
To read the full story
Related Article
- Rotavirus Vaccines Added to Public Vaccination Programs from Oct. 1, 2020: MHLW Panel
September 30, 2019
- MHLW Panel Backs Inclusion of Rotavirus Vaccines to Public Immunization Program
September 17, 2019
- Cost-Effectiveness Challenge Remains in Adding Rotavirus Vaccine to Public Vaccination Programs: MHLW Panel
August 5, 2019
- MHLW Vaccine Panel Discusses Inclusion of Rotavirus Vaccine in Public Vaccination Programs; Has “Enough Data”
June 7, 2019
REGULATORY
- LDP League Formally Urges Male HPV Shots Under NIP from FY2026
December 17, 2025
- MHLW Drafts Guideline Update, Urges Makers to Factor Distribution Costs into WPPs
December 16, 2025
- MHLW to Add Company-Driven Route to “Specific-Use Drug” Designations
December 16, 2025
- MHLW Council Determines 3 “Drug Loss” Products as High-Need, to Seek Development
December 16, 2025
- LDP Biosimilar Group Submits Request to Finance Minister, Seeks Continued Support
December 16, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…